Please enable JS

ARTICLES & TESTIMONIALS

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

July 12th – GHLF testimony and recommendation to FDA on proposed biosimilar to HUMIRA (adalimumab)

Jul 15// FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE

July 13th – GHLF FDA Arthritis Advisory Committee comments on proposed biosimilar to ENBREL (etanercept)

Jul 15// FDA Testimony Letters and Testimony

The committee will discuss biologics license application (BLA) 761024, for ABP 501, a proposed biosimilar to AbbVie Inc.’s HUMIRA (adalimumab), submitted by Amgen, Inc.

READ MORE